The exceedingly effective BioNTech-Pfizer vaccine developed for the novel coronavirus has been approved for use by the European Union, providing a first glimpse at hope for its populations.
According to reports, the European Medicines Agency greenlighted its approval by reassuring the vaccine meets the criteria for safeness and quality standards.
The move to begin wide-scale distributions of the new vaccine came at a time when confirmed cases of the recent coronavirus strain had begun to surge in numerous European nations.
But by the end of December, the European Union is expected to receive its deliveries of vaccines from BioNTech-Pfizer, potentially bringing the pandemic to a halt, or at best, minimizing its catastrophe.
BioNTech-Pfizer’s creation is just one of a few vaccines approved for immediate widespread use due to its high-efficiency rates; the other vaccines include Russia’s Sputnik V and another creation by biotechnology giant Moderna.
As of the final days of Q4 2020, the COVID-19 pandemic yielded close to 100 million confirmed cases worldwide and a rising death toll in the millions.
